MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.00
-0.90
-5.66%
Closed 16:41 10/20 EDT
OPEN
15.93
PREV CLOSE
15.90
HIGH
16.18
LOW
14.72
VOLUME
90.39K
TURNOVER
--
52 WEEK HIGH
26.67
52 WEEK LOW
10.63
MARKET CAP
493.25M
P/E (TTM)
-6.1718
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Piling Into Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the second quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]
Insider Monkey · 6d ago
Spruce Biosciences Proposes $75 Million IPO Terms
Spruce Biosciences has filed to raise $75 million in an IPO.The firm is developing treatments for rare endocrine disorders.Early trial results have been impressive and the IPO appears reasonably priced, so is worth a look for long-term hold life science investors.
Seekingalpha · 10/06 20:22
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S
GlobeNewswire · 09/21 12:30
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation From FDA For CRN04777 For The Treatment Of Congenital Hyperinsulinism
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Benzinga · 09/21 11:31
Crinetics Pharmaceuticals To Present New Data From Paltusotine And ACTH Antagonist Development Programs At European Congress Of Endocrinology Sept. 5-9
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Benzinga · 09/04 11:32
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that a presentation
GlobeNewswire · 09/04 11:30
Crinetics Pharmaceuticals to Participate in September Investor Conferences
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below: Baird Global Healthcare
GlobeNewswire · 09/03 22:56
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment
GlobeNewswire · 09/03 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRNX. Analyze the recent business situations of Crinetics Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRNX stock price target is 34.00 with a high estimate of 40.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 33.39M
% Owned: 101.53%
Shares Outstanding: 32.88M
TypeInstitutionsShares
Increased
41
7.71M
New
31
4.76M
Decreased
8
1.70M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Independent Director
Wendall Wierenga
President/Chief Executive Officer/Director
R. Scott Struthers
Chief Financial Officer
Marc Wilson
Vice President/Director of Human Resources
Adriana Cabre
Other
Alan Krasner
Other
Ajay Madan
Independent Director
Camille Bedrosian
Independent Director
Matthew Fust
Independent Director
Stephen Kaldor
Independent Director
Weston Nichols
Independent Director
Stephanie Okey
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Crinetics Pharmaceuticals Inc stock information, including NASDAQ:CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.